clinical trial · NCT03768063
A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study
Hoffmann-La Roche·phase3·active not recruiting·n = 1,000
CancerAtezolizumabBevacizumabAlectinibCobimetinibVemurafenibFAP IL2VVenetoclaxEnzalutamide
brief summary
This is an open-label, multicenter, extension study. Patients who are receiving clinical benefit from atezolizumab monotherapy or atezolizumab in combination with other agent(s) or combination/comparator agent(s) during participation in a Genentech or Roche-sponsored study (the parent study), who are eligible to continue treatment and who do not have access to the study treatment locally, may continue to receive study treatment in this extension study following roll-over from the parent study.
started
Feb 28, 2019
primary completion
Jul 5, 2028
completion
Jul 5, 2028
last updated
Jan 29, 2026
official title
An Open Label, Multicenter Extension Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella B)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol